On Dec. 30, 2020, Medigen Vaccine Biologics announced that it had obtained TFDA Phase 2 IND approval of MVC-COV1901 on December 29, 2020. MVC’s COVID-19 vaccine is composited of recombinant S-2P licensed from US NIH, and Dynavax’s proprietary CpG 1018 adjuvant, to induce desired immune response.

MVC had completed preclinical toxicology test, hamster challenge study, and phase 1 clinical trial interim analysis report. All data showed MVC-COV1901 offers a good safety profile and strong immunogenicity against COVID-19.